Dr Matthew Campbell (TCD) explains the latest developments out of the Trinity lab in the development of new drug therapies to treat Age-related Macular Degeneration.

1. Matthew Campbell Ocular Genetics Unit, TCD Neuronal barrier modulation: a new technology for preservation of vision

9. Permeability experiments using Gadolinium-diethyenetriamine-penta-acetic acid injection Magnetic Resonance Imaging (MRI) Gd-DTPA has a MW of 742 Daltons

10. Ocular drug delivery by barrier modulation

12. Laser induced Choroidal neovascularisation (CNV) Administered Doxycycline in drinking water for 2 weeks while receiving 2 I.P injections of VEGF receptor antagonist Sunitinib malate (532 Da)

13. “ The rationale was not to develop an RNAi therapeutic agent per se, but to use RNAi to allow the application of conventional drugs for treating diseases of the brain, CNS or eye”. [Professor John Rossi, commenting on the technology of Neuronal Barrier Modulation, EMBO Molecular Medicine, 2011]

17. Volume rendering of TBIs Cold-induced edema of the visual neocortex in mice – a model of TBI (high resolution T2 imaging)

18. NT siRNA CLDN5 siRNA 24 hr 48 hr 72 hr

24. Induced permeability of the blood-tumour barrier

25. The Ocular Genetics Unit at TCD Prof. Pete Humphries Dr. Marian Humphries Dr. Anna-Sophia Kiang Dr. Paul Kenna Prof Jane Farrar Ms Anh Nguyen Mr Finnian Hanrahan Mr James Keaney Ms Ema Ozaki